EMEA-001858-PIP02-16-M03

Key facts

Invented name
Vyxeos liposomal (previously known as Vyxeos)
Active substance
  • daunorubicin
  • cytarabine
Therapeutic area
Oncology
Decision number
P/0292/2019
PIP number
EMEA-001858-PIP02-16-M03
Pharmaceutical form(s)
Powder for concentrate for infusion
Condition(s) / indication(s)
Treatment of acute myeloid leukaemia
Route(s) of administration
Intravenous use
Contact for public enquiries
Jazz Pharmaceuticals Ireland Limited

E-mail: michael.chiarella@jazzpharma.com
Tel. +1 6092436211

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating